CONTRIBUTORS

p. 888-892 August 2019, Vol.25, No.4 doi: 10.1212/01.CON.0000578728.22103.71
CONTRIBUTORS
BROWSE ARTICLES

Elan D. Louis, MD, MS, FAAN, Guest Editor

Professor, Department of Neurology, Department of Epidemiology (Chronic Diseases); Chief, Division of Movements Disorders, Yale School of Medicine, Yale University, New Haven, Connecticut

Relationship Disclosure: Dr Louis serves on the clinical advisory boards of CADENT Therapeutics and SAGE Therapeutics, Inc and receives publishing royalties from Elsevier for Merritt’s Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Louis discusses the unlabeled/investigational use of alprazolam, benzodiazepines, carbidopa/levodopa, clonazepam, gabapentin, primidone, and topiramate for the treatment of essential tremor; trihexyphenidyl for the treatment of dystonic tremor; acetazolamide, baclofen, carbamazepine, clonazepam, ethosuximide, and phenytoin for the treatment of orthostatic tremor; pregabalin for the treatment of neuropathic tremor; benzodiazepines for the treatment of parkinsonian resting tremor; and phenobarbital to treat the side effects of acute nausea and unsteadiness that occur as a result of other treatments for tremor.

John N. Caviness, MD, FAAN

Professor, Department of Neurology, Consultant in Neurology, Mayo Clinic, Phoenix, Arizona

Relationship Disclosure: Dr Caviness reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Caviness discusses the unlabeled/investigational use of anticholinergic medications, botulinum toxin, carbamazepine, clonazepam, deep brain stimulation, levetiracetam, sodium oxybate, and tetrabenazine for the treatment of myoclonus.

Joseph H. Friedman, MD, FAAN, FANA

Director, Movement Disorders Program, Butler Hospital; Professor, Chief, Division of Movement Disorders, Warren Alpert Medical School, Brown University, Providence, Rhode Island

Relationship Disclosure: Dr Friedman has received honoraria from Cambridge University Press, MedLink, and Springer Press. He has received research/grant support as site investigator of clinical studies for the Michael J. Fox Foundation for Parkinson’s Research and the National Institutes of Health.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Friedman discusses the unlabeled/investigational use of α-methyl-para-tyrosine, botulinum toxin, clozapine, deep brain stimulation, reserpine, and tetrabenazine for the treatment of tardive syndromes.

Paul Greene, MD

Associate Professor, Neurology, Mount Sinai School of Medicine, New York, New York

Relationship Disclosure: Dr Greene reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Greene discusses the unlabeled/investigational use of medications for the treatment of atypical parkinsonism, none of which have been approved by the US Food and Drug Administration.

Joseph Jankovic, MD, FAAN

Professor, Department of Neurology; Distinguished Chair in Movement Disorders; Director, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas

Relationship Disclosure: Dr Jankovic has received personal compensation for serving on the advisory boards of and as a consultant for Parexel; Retrophin, Inc; and Teva Pharmaceutical Industries Ltd. Dr Jankovic has received personal compensation as an editor for and has received royalties from Cambridge University Press, Elsevier, Future Science Group, and Hodder Arnold. Dr Jankovic has received research/grant support from Allergan, CHDI Foundation, Dystonia Coalition, F. Hoffman-La Roche AG, Huntington Study Group, Michael J. Fox Foundation for Parkinson’s Research, and the National Institutes of Health.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Jankovic reports no disclosure.

H. A. Jinnah, MD, PhD

Professor, Department of Neurology, Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia

Relationship Disclosure: Dr Jinnah has received personal compensation for serving on the advisory boards of and as a consultant for Abide Therapeutics, Inc; Allergan, Inc; CoA Therapeutics; the International Neurotoxin Society; the International Parkinson and Movement Disorders Society; Medtronic; the Parkinson’s Foundation; Psyadon Pharmaceuticals Inc; Retrophin, Inc; and Saol Therapeutics. Dr Jinnah has received grant support from the Benign Essential Blepharospasm Research Foundation, Cavion, Cure Dystonia Now, the Dystonia Study Group, Ipsen Group, National Institutes of Health (NIH), and Retrophin, Inc. He also is principle investigator for the Dystonia Coalition, which receives the majority of its support through NIH grant TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and previously received support through grant NS065701 from the National Institutes of Neurological Disorders and Stroke. The Dystonia Coalition has received additional material or administrative support from industry sponsors (Allergan, Inc and Merz Pharmaceuticals) as well as private foundations (the American Dystonia Society, Beat Dystonia, the Benign Essential Blepharospasm Research Foundation, Cure Dystonia Now, Dystonia Europe, Dystonia Inc, Dystonia Ireland, the Dystonia Medical Research Foundation, the Foundation for Dystonia Research, the National Spasmodic Dysphonia Association, and the National Spasmodic Torticollis Association).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Jinnah discusses the unlabeled/investigational use of alprazolam, amphetamines, baclofen, benzodiazepines, benztropine, biperiden, botulinum neurotoxins, carbamazepine, carbidopa/levodopa, carisoprodol, chlordiazepoxide, chlorzoxazone, clonazepam, cyclobenzaprine, cyproheptadine, diazepam, ethopropazine, gabapentin, lithium, metaxalone, methocarbamol, nabilone orphenadrine, procyclidine, riluzole, tizanidine, trihexyphenidyl, and zolpidem for the treatment of dystonia. Dr Jinnah discusses the unlabeled/investigational use of thiamine for the treatment of biotin-thiamine–responsive basal ganglia disorder; folinic acid for the treatment of cerebral folate deficiency; chenodeoxycholic acid for the treatment of cerebrotendinous xanthomatosis; 5-hydroxytryptophan and tetrahydrobiopterin for the treatment of dopa-responsive dystonia; cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency; N-butyl-deoxynojirimycin for the treatment of Niemann-Pick disease type C; tetrabenazine for the treatment of oromandibular dystonia; and deutetrabenazine, tetrabenazine, and valbenazine and for the treatment of tardive dystonia.

Joseph S. Kass, MD, JD, FAAN

Associate Dean, Office of Student Affairs; Professor of Neurology, Psychiatry, and Medical Ethics; Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine; Chief of Neurology, Ben Taub General Hospital, Houston, Texas

Relationship Disclosure: Dr Kass serves as associate editor of medicolegal issues for Continuum, as an associate editor for Continuum Audio, as a neurology section editor of Ferri’s Clinical Advisor for Elsevier, and as co-editor of Neurology Secrets, Sixth Edition. Dr Kass has received personal compensation for CME lectures from Pri-Med LLC.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kass reports no disclosure.

Sheng-Han Kuo, MD

Assistant Professor, Department of Neurology, Columbia University, New York, New York

Relationship Disclosure: Dr Kuo has received personal compensation for serving on the medical advisory board of the International Essential Tremor Foundation and on the research advisory board of the National Ataxia Foundation. Dr Kuo has received research/grant support from the American Brain Research Training Fellowship, American Parkinson Disease Association, International Essential Tremor Foundation, the Louis V. Gerstner Jr Scholarship, National Ataxia Foundation, for the National Institute of Environmental Health Sciences pilot grant ES009089, as principal investigator for studies from the National Institute of Neurological Disorders and Stroke (R01 NS104423, K08 NS083738), Parkinson’s Foundation, and the Rare Disease Clinical Research Network (RC1NS068897).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kuo discusses the unlabeled/investigational use of amantadine, baclofen, chlorzoxazone, and riluzole for the treatment of cerebellar ataxia; 4-aminopyridine for the treatment of episodic ataxia type 2; deep brain stimulation for the treatment of spinocerebellar ataxia type 2; miglustat for the treatment of Niemann-Pick disease type C; and varenicline for spinocerebellar ataxia type 3.

Toni S. Pearson, MBBS

Associate Professor, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri

Relationship Disclosure: Dr Pearson has received research/grant support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Pearson reports no disclosure.

Roser Pons, MD

Associate Professor, Department of Pediatric Neurology, National and Kapodistrian University of Athens, Athens, Greece

Relationship Disclosure: Dr Pons has received personal compensation for serving as a consultant for and on the scientific advisory board of Biogen, for serving as a consultant for Guidepoint on a rare metabolic disorder, and for serving as a speaker for Biogen and for PTC Therapeutics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Pons reports no disclosure.

Rachel V. Rose, JD, MBA

Attorney, Rachel V. Rose Attorney at Law PLLC; Affiliated Faculty, Baylor College of Medicine, Houston, Texas

Relationship Disclosure: Ms Rose serves on the editorial board of BC Advantage and receives book royalties from the American Bar Association.

Unlabeled Use of Products/Investigational Use Disclosure: Ms Rose reports no disclosure.

Harvey S. Singer, MD, FAAN

Professor of Neurology and Pediatrics, Department of Neurology, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, Baltimore, Maryland

Relationship Disclosure: Dr Singer serves as a consultant for Abide Therapeutics, Inc; Cello Health BioConsulting; ClearView Healthcare Partners; Teva Pharmaceutical Industries Ltd; and Trinity Partners, LLC. Dr Singer receives publishing royalties from Elsevier and research/grant support from the Tourette Association of America.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Singer discusses the unlabeled/investigational use of baclofen, botulinum toxin, cannabidiol, clonazepam, clonidine, deutetrabenazine, ecopipam, fluphenazine, guanfacine, nabiximols, risperidone, sulpiride, tetrabenazine, Δ-9-tetrahydrocannibinol, tiapride, topiramate, and valbenazine.

Pichet Termsarasab, MD

Consultant Neurologist, Neurology Division/Department of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Relationship Disclosure: Dr Termsarasab serves as associate editor of the Journal of Clinical Movement Disorders and on the editorial board of Brain Science Journal. Dr Termsarasab has received personal compensation for speaking engagements for the American Academy of Neurology and Novartis AG and receives publishing royalties from MedLink Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Termsarasab discusses the unlabeled/investigational use of the current recommended treatments of chorea, none of which are approved by the US Food and Drug Administration except the use of deutetrabenazine for the treatment of chorea associated with Huntington disease and tardive dyskinesia, tetrabenazine for the treatment of chorea associated with Huntington disease, and valbenazine for the treatment of tardive dyskinesia.

Mary Ann Thenganatt, MD

Neurologist, University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Thenganatt has received an honorarium from MedLink Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Thenganatt reports no disclosure.

Theresa A. Zesiewicz, MD, FAAN

Professor, Department of Neurology, Director, Frances J. Zesiewicz Foundation for Parkinson’s Disease, Co-director, Movement Disorders Neuromodulation Center, University of South Florida; Director, Parkinson’s Disease Research, Education, and Clinical Center, Parkinson’s Disease Center at the James A. Haley Veteran’s Administration Hospital, Tampa, Florida

Relationship Disclosure: Dr Zesiewicz has received personal compensation for serving on the advisory boards of Boston Scientific; Reata Pharmaceuticals, Inc; and Steminent Biotherapeutics. Dr Zesiewicz has received personal compensation as senior editor for Neurodegenerative Disease Management and as a consultant for Steminent Biotherapeutics. Dr Zesiewicz has received royalty payments as co-inventor of varenicline for treating imbalance (patent number 9,463,190) and nonataxic imbalance (patent number 9,782,404). Dr Zesiewicz has received research/grant support as principal investigator/investigator for studies from AbbVie Inc; Biogen; Biohaven Pharmaceutics; Boston Scientific; Bukwang Pharmaceuticals Co, Ltd; Cala Health, Inc; Cavion; Friedreich’s Ataxia Research Alliance; Houston Methodist Research Institute; National Institutes of Health (READISCA U01); Retrotope Inc; and Takeda Development Center Americas, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Zesiewicz reports no disclosure.

Self-Assessment and CME Test Writers

Adam G. Kelly, MD

Associate Professor of Neurology; Chief, Neurovascular Division, University of Florida, Gainesville, Florida

Relationship Disclosure: Dr Kelly has received personal compensation as CME editor of Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kelly reports no disclosure.

Allison L. Weathers, MD, FAAN

Associate Chief Medical Information Officer, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Relationship Disclosure: Dr Weathers serves on the editorial board of Continuum and as chair of the adult neurosciences specialty steering board for Epic.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Weathers reports no disclosure.

© 2019 American Academy of Neurology.